Ibrahim Aldoss, MD

AZD0486 demonstrated encouraging safety and dose-dependent efficacy in heavily pretreated adolescent and adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), according to early findings from the phase 1/2 SYRUS trial and Ibrahim Aldoss, MD, of City of Hope.

Ibrahim Aldoss, MD, discusses the potential of AZD0486 for treating relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and outlines the SYRUS study objectives.

Ponatinib shows promising results in achieving MRD negativity and improved event-free survival in Ph+ ALL patients compared to imatinib, according to ASCO findings.

Ibrahim Aldoss, MD, associate professor, City of Hope, explores recent findings on ponatinib as a first-line treatment for Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).